The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response

被引:46
作者
Cascini, Caterina [1 ]
Chiodoni, Claudia [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, I-20133 Milan, Italy
关键词
osteosarcoma; tumor microenvironment; macrophages; bone marrow; osteoclasts; mesenchymal stem cells; MESENCHYMAL STEM-CELLS; TUMOR-ASSOCIATED MACROPHAGES; T-CELLS; GROWTH; EXPRESSION; ROLES; POLARIZATION; INFILTRATION; SUPPRESSION; OSTEOCLASTS;
D O I
10.3390/cells10071668
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Osteosarcoma (OS) is a high-grade malignant stromal tumor composed of mesenchymal cells producing osteoid and immature bone, with a peak of incidence in the second decade of life. Hence, although relatively rare, the social impact of this neoplasm is particularly relevant. Differently from carcinomas, molecular genetics and the role of the tumor microenvironment in the development and progression of OS are mainly unknown. Indeed, while the tumor microenvironment has been widely studied in other solid tumor types and its contribution to tumor progression has been definitely established, tumor-stroma interaction in OS has been quite neglected for years. Only recently have new insights been gained, also thanks to the availability of new technologies and bioinformatics tools. A better understanding of the cross-talk between the bone microenvironment, including immune and stromal cells, and OS will be key not only for a deeper knowledge of osteosarcoma pathophysiology, but also for the development of novel therapeutic strategies. In this review, we summarize the current knowledge about the tumor microenvironment in OS, mainly focusing on immune cells, discussing their role and implication for disease prognosis and treatment response.
引用
收藏
页数:13
相关论文
共 71 条
[1]   Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts [J].
Akiyama, Toru ;
Dass, Crispin R. ;
Shinoda, Yusuke ;
Kawano, Hirotaka ;
Tanaka, Sakae ;
Choong, Peter F. M. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 62 (04) :470-476
[2]   Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway [J].
Akiyama, Toru ;
Dass, Crispin R. ;
Choong, Peter F. M. .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (11) :3461-3469
[3]   The paradox of Th17 cell functions in tumor immunity [J].
Asadzadeh, Zahra ;
Mohammadi, Hamed ;
Safarzadeh, Elham ;
Hemmatzadeh, Maryam ;
Mahdian-Shakib, Ahmad ;
Jadidi-Niaragh, Farhad ;
Azizi, Gholamreza ;
Baradaran, Behzad .
CELLULAR IMMUNOLOGY, 2017, 322 :15-25
[4]   Increased osteoclast activity is associated with aggressiveness of osteosarcoma [J].
Avnet, Sofia ;
Longhi, Alessandra ;
Salerno, Manuela ;
Halleen, Jussi M. ;
Perut, Francesca ;
Granchi, Donatella ;
Ferrari, Stefano ;
Bertoni, Franco ;
Giuti, Armando ;
Baldini, Nicola .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (06) :1231-1238
[5]   Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression [J].
Baglio, S. Rubina ;
Lagerweij, Tonny ;
Perez-Lanzon, Maria ;
Ho, Xuan Dung ;
Leveille, Nicolas ;
Melo, Sonia A. ;
Cleton-Jansen, Anne-Marie ;
Jordanova, Ekaterina S. ;
Roncuzzi, Laura ;
Greco, Michelina ;
van Eijndhoven, Monique A. J. ;
Grisendi, Giulia ;
Dominici, Massimo ;
Bonafede, Roberta ;
Lougheed, Sinead M. ;
de Gruijl, Tanja D. ;
Zini, Nicoletta ;
Cervo, Silvia ;
Steffan, Agostino ;
Canzonieri, Vincenzo ;
Martson, Aare ;
Maasalu, Katre ;
Koks, Sulev ;
Wurdinger, Tom ;
Baldini, Nicola ;
Pegtel, D. Michiel .
CLINICAL CANCER RESEARCH, 2017, 23 (14) :3721-3733
[6]   Understanding the tumor immune microenvironment (TIME) for effective therapy [J].
Binnewies, Mikhail ;
Roberts, Edward W. ;
Kersten, Kelly ;
Chan, Vincent ;
Fearon, Douglas F. ;
Merad, Miriam ;
Coussens, Lisa M. ;
Gabrilovich, Dmitry I. ;
Ostrand-Rosenberg, Suzanne ;
Hedrick, Catherine C. ;
Vonderheide, Robert H. ;
Pittet, Mikael J. ;
Jain, Rakesh K. ;
Zou, Weiping ;
Howcroft, T. Kevin ;
Woodhouse, Elisa C. ;
Weinberg, Robert A. ;
Krummel, Matthew F. .
NATURE MEDICINE, 2018, 24 (05) :541-550
[7]   Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells [J].
Bonuccelli, Gloria ;
Avnet, Sofia ;
Grisendi, Giulia ;
Salerno, Manuela ;
Granchi, Donatella ;
Dominici, Massimo ;
Kusuzaki, Katsuyuki ;
Baldini, Nicola .
ONCOTARGET, 2014, 5 (17) :7575-7588
[8]   Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents [J].
Buddingh, Emilie P. ;
Kuijjer, Marieke L. ;
Duim, Ronald A. J. ;
Buerger, Horst ;
Agelopoulos, Konstantin ;
Myklebost, Ola ;
Serra, Massimo ;
Mertens, Fredrik ;
Hogendoorn, Pancras C. W. ;
Lankester, Arjan C. ;
Cleton-Jansen, Anne-Marie .
CLINICAL CANCER RESEARCH, 2011, 17 (08) :2110-2119
[9]   BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma [J].
Cao, Hongxin ;
Quan, Shuang ;
Zhang, Lu ;
Chen, Yunzhen ;
Jiao, Guangjun .
ONCOLOGY LETTERS, 2021, 21 (05)
[10]   RANKL blockade prevents and treats aggressive osteosarcomas [J].
Chen, Yan ;
Di Grappa, Marco A. ;
Molyneux, Sam D. ;
McKee, Trevor D. ;
Waterhouse, Paul ;
Penninger, Josef M. ;
Khokha, Rama .
SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (317)